{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': 'Dibrell Building',
 'address2': 'Suite A-100 302 East Pettigrew Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.43,
 'askSize': 1100,
 'averageDailyVolume10Day': 484300,
 'averageVolume': 647031,
 'averageVolume10days': 484300,
 'beta': None,
 'beta3Year': None,
 'bid': 7.2,
 'bidSize': 1300,
 'bookValue': 2.236,
 'category': None,
 'circulatingSupply': None,
 'city': 'Durham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.8,
 'dayLow': 7.39,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.721,
 'enterpriseToRevenue': 10.15,
 'enterpriseValue': 241310784,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '480-393-5553',
 'fiftyDayAverage': 8.151857,
 'fiftyTwoWeekHigh': 23.67,
 'fiftyTwoWeekLow': 4.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42053870,
 'forwardEps': -2.16,
 'forwardPE': -3.4305553,
 'fromCurrency': None,
 'fullTimeEmployees': 225,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.120620005,
 'heldPercentInstitutions': 0.54998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/precisionbiosciences.com',
 'longBusinessSummary': 'Precision BioSciences, Inc. operates as a genome '
                        'editing company and develops therapeutic products in '
                        'the United States. It operates through two segments, '
                        'Therapeutic and Food. The company offers ARCUS, a '
                        'genome editing platform to cure cancers and genetic '
                        'disorders. The Therapeutic segment develops '
                        'allogeneic CAR T immunotherapy that recognizes and '
                        'kills cancer cells; and engages in the in vivo gene '
                        'correction activities. This segment develops '
                        'PBCAR0191, is an allogeneic CAR T cell therapy '
                        'targeting the tumor target CD19 for acute '
                        'lymphoblastic leukemia and non-hodgkin lymphoma; and '
                        'CD20, BCMA, and CLL-1, CAR T cell therapies targeting '
                        'the tumor antigens. The Food segment develops food '
                        'and nutrition products; and pre-breeding materials, a '
                        'gene edited crop intermediate that could be '
                        'integrated into breeding program and use in producing '
                        'new crop varieties. The company has development and '
                        'commercial license agreement with Shire Plc for '
                        'research and development of individual T cell '
                        'modifications; collaboration agreement with Gilead '
                        'Sciences, Inc. to co-develop a product candidate to '
                        'cure chronic Hepatitis B infection. Precision '
                        'BioSciences, Inc. was founded in 2006 and is '
                        'headquartered in Durham, North Carolina.',
 'longName': 'Precision BioSciences, Inc.',
 'market': 'us_market',
 'marketCap': 384292960,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_41018856',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -87930000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.76,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '919-314-5512',
 'previousClose': 7.85,
 'priceHint': 2,
 'priceToBook': 3.3139534,
 'priceToSalesTrailing12Months': 16.164421,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.8,
 'regularMarketDayLow': 7.39,
 'regularMarketOpen': 7.76,
 'regularMarketPreviousClose': 7.85,
 'regularMarketPrice': 7.76,
 'regularMarketVolume': 526524,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 51861400,
 'sharesPercentSharesOut': 0.043899998,
 'sharesShort': 2277800,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1630383,
 'shortName': 'Precision BioSciences, Inc.',
 'shortPercentOfFloat': 0.0499,
 'shortRatio': 2.68,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'DTIL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.73,
 'twoHundredDayAverage': 7.913993,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '3c610058-9f43-33c6-b360-7e8a0bce4509',
 'volume': 526524,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.precisionbiosciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27701'}